Role and Place of Modern Macrolides in the Treatment of Bacterial Infections | CMAC

Role and Place of Modern Macrolides in the Treatment of Bacterial Infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(1):78-84

Section
Information
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(1):78-84
  • 1. Практическое руководство по антиинфекционной химиотерапии. Под редакцией Л.С. Страчунского, Ю.Б. Белоусова, С.Н. Козлова. Смоленск МАКМАХ, 2007. - 464 с.
  • 2. Sahm DF, Brown NP, Draghi DC, et al. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med 2008; 120 (3 Suppl 1):8-15.
  • 3. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-
  • 4. Ann Clin Microbiol Antimicrob 2008; 7:1. 4. Critchley IA, Brown SD, Traczewski MM, et al. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U. S. Faropenem surveillance study. Antimicrob Agents Chemother 2007; 51(12):4382-9.
  • 5. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009; 15(8):1260-4.
  • 6. Sahm DF, Brown NP, Thornsberry C, et al. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med 2008; 120(3 Suppl 1):16-24.
  • 7. Козлов Р.С. и др. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999-2009 гг. Клин микробиол и антимикроб химиотер. 2010; 12(4):329-41.
  • 8. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11(2):137-52.
  • 9. Portier H, Filipecki J, Weber P, et al. Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: a multi-centre, openlabel, randomized study. J Antimicrob Chemother 2002; 49(2):337-44.
  • 10. Norrby SR, Quinn J, Rangaraju M, et al. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis. Clin Microbiol Infect 2004; 10(7):615-23.
  • 11. Ioannidis JP, Contopoulos-Ioannidis DG, Chew P, et al. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. J Antimicrob Chemother 2001; 48(5):677-89.
  • 12. Quinn J, Ruoff GE, Ziter PS. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study. Clin Ther 2003; 25(2):422-43.
  • 13. McCarty JM, Phillips A, Wiisanen R. Comparative safety and efficacy of clarithromycin and amoxicillin/ clavulanate in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993; 12(12): S122-7.
  • 14. Henry DC, Riffer E, Sokol WN, et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003; 47(9):2770-4.
  • 15. Adelglass J, Jones TM, Ruoff G, et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy 1998; 18(6):1255-63.
  • 16. Stefansson P, Jacovides A, Jablonicky P, et al. Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. Rhinology 1998; 36(4):173-8.
  • 17. Riffer E, Spiller J, Palmer R, et al. Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study. Curr Med Res Opin 2005; 21(1):61-70.
  • 18. Castrellon PG, et al. Efficasy and safety of clarithromycin in pediatric patients with upper respiratory infections: a systematic review with meta-analysis. Revista de Investigacion Clinica 2012; 64(2):126-35.
  • 19. Siempos I., Dimopoulos G., Korbila I., et al. Macrolides, quinolones and amoxicillin/ clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29:1127- 37.
  • 20. Hess G, Hill JW, Raut MK, et al. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: results from a claims analysis. Adv Ther 2010; 27(10):743-55.
  • 21. Hoeffken G, Meyer HP, Winter J, et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001; 95(7):553-64.
  • 22. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002; 24(5):736-51.
  • 23. Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 2004; 3(5):329-36.
  • 24. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002; 24(8):1292-308.
  • 25. Correa JC, Badaro R, Bumroongkit C, et al. Randomized, open-label, parallelgroup, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin Ther 2003; 25(5):1453-68.
  • 26. Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11(8):589-93.
  • 27. GarciaVazquez E, Mensa J, Martinez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactamagent alone. Eur J Clin Microbiol Infect Dis 2005; 24(3):190-5.
  • 28. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a betalactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36(4):389-95.
  • 29. Restrepo MI. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33:153-9.
  • 30. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. Dec 15 1994; 121(12):905-11.
  • 31. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med. Aug 8 1996; 335(6):377-83.
  • 32. Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis. Nov 1998; 27(5):1278-85.
  • 33. Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis. May 1999; 28(5):1080-5.
  • 34. Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/ Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis. Apr 2000; 181(4):1289-97.
  • 35. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed (15.07.2013) [pp. 87-96].
  • 36. Malfertheiner P, et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut. 2012 May; 61(5):646-64.
  • 37. Саблин О.А. и соавт. Факторы, определяющие эффективность эрадикационной терапии Helicobacter рyloriассоциированных заболеваний. Консилиум Медикум. Гастроэнтерология, 2011; 2:34-38.
  • 38. Дехнич Н.Н., Костякова Е.А., Пунин А.А., Алимов А.В., Иванчик Н.В., Козлов Р.С. Антибиотикорезистентность H. pylori: результаты микробиологического регионального исследования // РЖГГК 2011; 21(2):37-42.
  • 39. Бокарев А.А., Перфилова К.М. и соавт. Устойчивость Helicobacter pylori к макролидам у больных c Н. pyloriпозитивной гастродуоденальной патологией. Материалы II Ежегодного Всероссийского Конгресса по инфекционным болезням. Москва, 29-31 марта 2010 г.
  • 40. Осипенко М.Ф., Бикбулатова Е.А., Шакалите Ю.Д. и соавт. Резистентность Helicobacter pylori к кларитромицину в Новосибирске // Рос журн гастроэнт гепатол колопроктол. 2012; 5(прил. 40):36.
  • 41. Ивашкин В. Т., Маев И. В., Лапина Т. Л., Шептулин А. А. Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. РЖГГК 2012; 1:87-89.
  • 42. Подзолкова Н.М. и соавт. Этиология, патогенез и особенности антибактериальной терапии воспалительных заболеваний у молодых женщин. Гинекология 2010; 13(5):42-7.
  • 43. Lanjouw E, Ossewaarde JM, Stary A, et al. 2010 European guideline for the management of Chlamydia trachomatis infections // Int J STD AIDS. 2010; 21(11):729-37.
  • 44. Savaris RF, et al. Сomparing Ceftriaxone Plus Azithromycine or Doxycycline for Pelvic Inflammatory Disease. Obsted Gynecol 2007;110:53-60.
  • 45. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials // Sex Transm Dis 2002; 29(9):497-502.
  • 46. Wikstrom A., Jensen JS. Mycoplasma genitalium: a common cause of persistant urethritis among men treated with doxycycline. Sex Transm Infect 2006; 82:276-9.
  • 47. Клинические рекомендации. Акушерство и гинекология. - 4-е изд., перераб. и доп. под ред. Серова В.Н., Сухих Г.Т. - М.: ГЭОТАР-Медиа, 2014. - 1024с.: ил., с. 773, 778. Справочник по антимикробной терапии. Выпуск 3. Под редакцией Р.С. Козлова, А.В. Дехнича. - Смоленск: МАКМАХ, 2013. - 480с., с. 156.
  • 48. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Singledose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2007; 30:213-21.
  • 49. Ross J, Judlin P, Jensen 2012 European guideline for the management of pelvic inflammatory disease. J Int J STD AIDS. 2014 Jan; 25(1):1-7. doi: 10.1177/0956462413498714. Epub 2013 Aug 29.
  • 50. Williams JD. Evaluation of the safety of macrolides. Int Antimicrob Agents 18 (2001) S77-S81.
  • 51. Serranti D. Antibiotic induced liver injury: what about children? J of Chemotherapy 2013; 25(5):255-72.
  • 52. Синопальников А.И., Андреева И.В., Стецюк О.У. Безопасность макролидных антибиотиков: критический анализ. Клиническая медицина. 2012; 3:23-30.
  • 53. GuoetD, et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010 Sep; 65(9):631-40.
  • 54. Simko J, et al. Proarrhythmic Potential of Antimicrobial Agents. Infection 2008; 36:194-206.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared